Strengthening Proprietary Technologies and R&D Capabilities
First written in FY2016. 17 of 30 entries say "Restated". Latest entry: FY2026.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In genetic products, we obtained Japanese marketing approval in August 2025 for “Loopamp Malaria Pan Detection Reagent Kit” for detecting malaria parasites, “Loopamp Malaria Pf Detection Reagent Kit” for detecting Plasmodium falciparum, and “Loopamp Malaria Pv Detection Reagent Kit” for detecting Plasmodium vivax, and launched them in December 2025. In addition, “Loopamp MTBC Detection Kit” and 2 other products for detecting the Mycobacterium tuberculosis complex obtained WHO Prequalification (WHO-PQ) certification for in vitro diagnostic products in December 2025 and were added to the Prequalified In Vitro Diagnostic Products list.」
Commercialization of R&D results and acquisition of international certifications progressed through the approval and launch of 3 malaria products and WHO-PQ certification and listing of 3 products, including tuberculosis complex detection reagents. - FY2025AdvancedAnnual report
「Total R&D expenses for the current consolidated fiscal year amounted to ¥4,386 million.」
The company recognized ¥4,386 million in R&D expenses and advanced the strengthening of its R&D capabilities through concrete commercialization and collaboration, including obtaining approval for MINtS and entering into a comprehensive collaboration agreement with Institute of Science Tokyo. - FY2024-Q3RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative third quarter of the current consolidated fiscal year was ¥2,646 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative third-quarter R&D spending of ¥2,646 million. - FY2024-Q1RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative first quarter of the current consolidated fiscal year was ¥810 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative first-quarter R&D spending of ¥810 million. - FY2023AdvancedAnnual report
「The new research building under construction at the Nogi Facility in Tochigi Prefecture was completed and began full-scale operations in October 2022. Together with the existing research building at the same facility, the new building will form the “Comprehensive Research Center” and serve as a key base for the company’s R&D activities.」
Following completion and the start of full-scale operations at the new research building, the company progressed to the stage of integrating the research facility at the Nasu Facility into a Comprehensive Research Center to strengthen R&D and accelerate innovation. - FY2023-Q3AdvancedAnnual report
「Property, plant and equipment increased by ¥1,630 million following the start of operations at the new research building.」
The new research building began operations, advancing development of the R&D infrastructure from the construction stage to the operating stage, as reflected in the ¥1,630 million increase in property, plant and equipment. - FY2023-Q2RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative second quarter of the current consolidated fiscal year was ¥1,505 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative second-quarter R&D spending of ¥1,505 million. - FY2023-Q1RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative first quarter of the current consolidated fiscal year was ¥634 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative first-quarter R&D spending of ¥634 million. - FY2022AdvancedAnnual report
「In fiscal 2021, we entered into an agreement with Illumina and began developing a companion diagnostic system using a next-generation sequencer.」
Efforts to strengthen R&D capabilities progressed in fiscal 2021 with the signing of an agreement with Illumina and the start of development of a companion diagnostic system using a next-generation sequencer. - FY2022-Q3RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative third quarter of the current consolidated fiscal year was ¥2,244 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative third-quarter R&D spending of ¥2,244 million. - FY2022-Q2RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative second quarter of the current consolidated fiscal year was ¥1,411 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative second-quarter R&D spending of ¥1,411 million. - FY2022-Q1AdvancedAnnual report
「Property, plant and equipment increased by ¥1,384 million, mainly due to the recognition of construction in progress associated with the start of construction of the new research building.」
Construction in progress was recognized following the start of construction of the new research building, advancing development of the R&D infrastructure from the planning stage to the construction stage. - FY2021-Q3AdvancedAnnual report
「Nature of facility: Construction of a new research building Planned investment: Total ¥4,325 million Source of funds: Internal funds Start: June 2021 Completion: October 2022」
While stating that there were no material changes in R&D activities, the company newly finalized a self-funded construction plan for a new research building with a total investment of ¥4,325 million, scheduled to start in June 2021 and be completed in October 2022. - FY2021-Q2RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative second quarter of the current consolidated fiscal year was ¥1,338 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative second-quarter R&D spending of ¥1,338 million. - FY2020AdvancedAnnual report
「We also advanced development of the testing chips used with this medical device, obtained regulatory approval for 2 chips covering a total of 5 test items, and secured reimbursement coverage. In April 2020, we launched the “Fully Automated Nucleic Acid Testing Instrument Simprova,” “Simprova Respiratory Infection Panel BP,LP,MP,” and “Simprova Extraction Kit/S1.”」
For Simprova, chip development progressed to regulatory approval for 2 chips covering a total of 5 test items, reimbursement coverage, and product launch. - FY2020-Q2RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative second quarter of the current consolidated fiscal year was ¥1,267 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative second-quarter R&D spending of ¥1,267 million. - FY2020-Q1RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative first quarter of the current consolidated fiscal year was ¥649 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative first-quarter R&D spending of ¥649 million. - FY2019AdvancedAnnual report
「For the compact, fully automated genetic testing system (Simprova) developed to address the medical need of “Near the patient,” we are advancing development of the instrument and the multi-item genetic testing chips, and have been submitting applications for marketing approval of respiratory infection test items on a sequential basis since June 2018. We will continue working toward an early launch.」
Simprova progressed from instrument and chip development to the application stage for marketing approval of respiratory infection test items. - FY2019-Q3RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative third quarter of the current consolidated fiscal year was ¥1,816 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative R&D spending of ¥1,816 million for the third quarter. - FY2019-Q2RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative second quarter of the current consolidated fiscal year was ¥1,218 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative R&D spending of ¥1,218 million for the second quarter. - FY2019-Q1RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative first quarter of the current consolidated fiscal year was ¥642 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative quarterly R&D spending of ¥642 million. - FY2018RestatedAnnual report
「In R&D, we will strengthen industry-government-academia collaboration and continue developing highly competitive next-generation products, primarily in our priority business areas.」
The company continues its policy of developing next-generation products, primarily in its priority business areas, and strengthening its R&D capabilities, with industry-government-academia collaboration identified as a means of implementation. - FY2018-Q3RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative third quarter of the current consolidated fiscal year was ¥1,825 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative quarterly R&D spending of ¥1,825 million. - FY2018-Q2RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative second quarter of the current consolidated fiscal year was ¥1,156 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported cumulative quarterly R&D spending of ¥1,156 million. - FY2018-Q1RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative first quarter of the current consolidated fiscal year was ¥585 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
While stating that there were no material changes in R&D activities, the company reported R&D spending of ¥585 million for the cumulative quarter. - FY2017AdvancedAnnual report
「For genetic testing reagents, the tuberculosis detection reagent kit for developing countries, “Loopamp Tuberculosis Complex Detection Reagent Kit,” and the “Loopamp PURE DNA Extraction Kit,” jointly developed with FIND, received WHO recommendations in August 2016 as replacements for, or additional tests to, smear microscopy. In July 2016, we launched “Loopamp Leishmania Detection Kit,” a reagent for detecting the protozoan that causes leishmaniasis, one of the neglected diseases, as a research-use reagent in Japan. In addition, “Loopamp Pertussis Detection Reagent Kit D,” launched in December 2015, became the first genetic testing reagent for Bordetella pertussis to receive reimbursement coverage.」
Commercialization and regulatory adoption of R&D results progressed, including the WHO recommendation, the launch of the Leishmania detection reagent, and the first reimbursement coverage for Pertussis Detection Reagent Kit D. - FY2017-Q3AdvancedAnnual report
「③ Strengthening R&D capabilities The company pursued product improvements through technological refinement and launched US-1200, the successor to the US-1000 automated urinalysis analyzer, in August 2016. In addition, the Loopamp Pertussis Detection Reagent Kit D, a nucleic acid kit for Bordetella pertussis based on the LAMP method, was listed for reimbursement under Japan’s national health insurance system in November 2016.」
In addition to the launch of US-1200, the LAMP-based nucleic acid kit for Bordetella pertussis was listed for reimbursement under Japan’s national health insurance system, marking progress in product improvement and commercialization. - FY2017-Q2AdvancedAnnual report
「③ Strengthening R&D capabilities The company pursued product improvements through technological refinement and launched US-1200, the successor to the US-1000 automated urinalysis analyzer, in August 2016.」
The company pursued technological improvements and launched US-1200 in August 2016. - FY2017-Q1RestatedAnnual report
「There were no material changes in the status of the Group’s R&D activities during the three months ended March 31, XXXX.」
The company stated that there had been no significant changes in its R&D activities, indicating that its existing policy remained in place. - FY2016First statedAnnual report
「② Strengthening proprietary technologies and R&D capabilities」
This is linked to the promotion of development of rapid tests, genetic tests and testing equipment.